Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 13,477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: cGVHD Clear all
Withdrawn Phase 2 Interventional

Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

NCT02574962
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
H.P. Acthar® Gel
Drug
Lead sponsor
Mamatha Pasnoor, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 25, 2026, 9:47 AM EDT
Not yet recruiting Phase 1 Interventional

Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease

NCT07696962
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ChoironeX GalKO Porcine Thymokidney
Biological
Lead sponsor
Xeno Holdings (US), LLC dba ChoironeX
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)

NCT05492903
View directory record Official record
Conditions
Pain Management, Ergonomics, Wounds and Injuries
Interventions
COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 25, 2026, 9:47 AM EDT
Recruiting No phase listed Observational

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions
Not listed
Lead sponsor
Brian Keller
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Study Comparing the Programmed Delay Between the Atrial and Ventricle Interval

NCT00794183
View directory record Official record
Conditions
Heart Failure
Interventions
CRT device settings
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 25, 2026, 9:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Disease and Chronic Periodontitis

NCT03369405
View directory record Official record
Conditions
Thyroid Diseases, Chronic Periodontitis
Interventions
NO intervention, patient records review only
Other
Lead sponsor
University at Buffalo
Other
Eligibility
35 Years and older
Enrollment
4,965 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 25, 2026, 9:47 AM EDT
Not listed Phase 1 Interventional

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

NCT00227461
View directory record Official record
Conditions
Aphasia, Stroke
Interventions
Wait first, then levetiracetam, Levetiracetam first, then wait
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 1 Interventional

Assessment of Coronary Plaque Composition Using Optical Coherence Tomography

NCT01642173
View directory record Official record
Conditions
Coronary Atherosclerosis, Endothelial Dysfunction, Coronary Small Vessel Disease
Interventions
Optical Coherence Tomography (C7 XR Dragonfly )
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

NCT03716505
View directory record Official record
Conditions
Migraine Disorders
Interventions
gammaCore Sapphire active, gammaCore Sapphire Sham
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Scottsdale, Arizona • Carlsbad, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

NCT00797953
View directory record Official record
Conditions
Angina Pectoris
Interventions
T89
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 25, 2026, 9:47 AM EDT
Recruiting Phase 1 Interventional

Augmenting Ankle Plantarflexor Function in Cerebral Palsy

NCT05154253
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Biomotum Spark: Robotic ankle assistance, Biomotum Spark: Robotic ankle resistance, Standard gait training, Ankle foot orthosis, Standard physical therapy, Standard walking
Device · Other
Lead sponsor
Northern Arizona University
Other
Eligibility
8 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
View directory record Official record
Conditions
End Stage Renal Disease, Rejection of Renal Transplant
Interventions
Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

NCT01598090
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Telaprevir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Anaheim, California • Garden Grove, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 25, 2026, 9:47 AM EDT
Active, not recruiting Not applicable Interventional

Brief Pain Reprocessing Therapy in Veterans

NCT06771713
View directory record Official record
Conditions
Chronic Lower Back Pain (CLBP)
Interventions
Brief Pain Reprocessing Therapy (BPRT)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

To Evaluate if the Medication Gabapentin Lessens Vulvar Pain

NCT00390013
View directory record Official record
Conditions
Vulvar Pain Symptoms, Vulvodynia (Chronic Vulvar Pain)
Interventions
Gabapentin, Placebo oral capsule
Drug
Lead sponsor
Colleen Stockdale
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 25, 2026, 9:47 AM EDT
Not listed No phase listed Observational

Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)

NCT05692713
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
St Louis, Missouri • Omaha, Nebraska • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 25, 2026, 9:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

NCT06940323
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional Results available

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

NCT00114959
View directory record Official record
Conditions
Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
Interventions
Homoharringtonine, Imatinib Mesylate
Drug
Lead sponsor
ChemGenex Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 25, 2026, 9:47 AM EDT
Withdrawn Phase 1Phase 2 Interventional

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

NCT02503280
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System
Drug · Device
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Not applicable Interventional

SOCIABLE Seniors Optimizing Community Integration to Advance Better Living With ESRD

NCT03055273
View directory record Official record
Conditions
ESRD, Social Behavior, Physical Disability
Interventions
SOCIABLE
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT01840956
View directory record Official record
Conditions
End-stage Renal Disease, Kidney Failure, Chronic
Interventions
HAVG
Biological
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Effect of Meso Wound Matrix in the Treatment of DFUs

NCT04182451
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs)
Interventions
Meso Wound Matrix
Device
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Pembroke Pines, Florida • Ford City, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 25, 2026, 9:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT05092451
View directory record Official record
Conditions
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
Interventions
Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 25, 2026, 9:47 AM EDT